Haizheng Pharmaceutical announced that its wholly-owned subsidiary Haizheng Pharmaceutical Co., Ltd.'s brief application for a new drug for fludarabine phosphate injection declared to the US FDA has been approved. This means Haizheng Hangzhou can sell this product in the US market. Fludarabine phosphate injection is a nucleoside metabolism inhibitor. The indications are: as a component of a combination treatment plan to treat adult B-cell chronic lymphocytic leukemia; for adult B-cell chronic lymphocytic leukemia patients who have previously received at least 1 type of alkylating agent that is not effective, or whose disease progresses during treatment.

Haizheng Pharmaceutical announced that its wholly-owned subsidiary Haizheng Pharmaceutical Co., Ltd.'s brief application for a new drug for fludarabine phosphate injection declared to the US FDA has been approved. This means Haizheng Hangzhou can sell this product in the US market. Fludarabine phosphate injection is a nucleoside metabolism inhibitor. The indications are: as a component of a combination treatment plan to treat adult B-cell chronic lymphocytic leukemia; for adult B-cell chronic lymphocytic leukemia patients who have previously received at least 1 type of alkylating agent that is not effective, or whose disease progresses during treatment.